IRIS
SARACINO, ANNALISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.457
AS - Asia 7.611
EU - Europa 6.361
SA - Sud America 1.958
Continente sconosciuto - Info sul continente non disponibili 1.265
AF - Africa 412
OC - Oceania 16
AN - Antartide 1
Totale 34.081
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.040
SG - Singapore 3.093
IT - Italia 2.474
BR - Brasile 1.483
CN - Cina 1.412
HK - Hong Kong 1.095
DE - Germania 797
VN - Vietnam 638
SE - Svezia 618
RU - Federazione Russa 596
FR - Francia 467
FI - Finlandia 375
BD - Bangladesh 337
GB - Regno Unito 320
IN - India 228
CA - Canada 202
UA - Ucraina 185
AR - Argentina 155
ID - Indonesia 136
CI - Costa d'Avorio 134
MX - Messico 107
NL - Olanda 106
IQ - Iraq 96
ZA - Sudafrica 91
EC - Ecuador 85
PK - Pakistan 82
PL - Polonia 78
TR - Turchia 72
CO - Colombia 65
JP - Giappone 61
VE - Venezuela 61
ES - Italia 55
AT - Austria 53
SA - Arabia Saudita 50
PH - Filippine 49
BE - Belgio 48
MA - Marocco 38
IE - Irlanda 36
CL - Cile 33
KE - Kenya 29
MY - Malesia 29
TN - Tunisia 29
JM - Giamaica 28
LT - Lituania 27
JO - Giordania 26
UZ - Uzbekistan 26
CZ - Repubblica Ceca 23
PY - Paraguay 22
PE - Perù 20
AE - Emirati Arabi Uniti 16
KZ - Kazakistan 16
CH - Svizzera 15
CR - Costa Rica 15
IL - Israele 15
AZ - Azerbaigian 14
DZ - Algeria 14
ET - Etiopia 14
PS - Palestinian Territory 14
AU - Australia 12
TW - Taiwan 12
UY - Uruguay 12
BO - Bolivia 11
EG - Egitto 11
GR - Grecia 11
HR - Croazia 11
NP - Nepal 11
RS - Serbia 11
TT - Trinidad e Tobago 11
LY - Libia 10
PA - Panama 10
HN - Honduras 8
KW - Kuwait 8
LB - Libano 8
AL - Albania 7
OM - Oman 7
QA - Qatar 7
BG - Bulgaria 6
BH - Bahrain 6
BY - Bielorussia 6
HU - Ungheria 6
IR - Iran 6
KR - Corea 6
NG - Nigeria 6
NI - Nicaragua 6
RO - Romania 6
SR - Suriname 6
SV - El Salvador 6
GT - Guatemala 5
KG - Kirghizistan 5
PT - Portogallo 5
TH - Thailandia 5
UG - Uganda 5
BZ - Belize 4
DO - Repubblica Dominicana 4
EU - Europa 4
GE - Georgia 4
GH - Ghana 4
GY - Guiana 4
LA - Repubblica Popolare Democratica del Laos 4
MZ - Mozambico 4
Totale 32.744
Salva come PNG Salva come JPEG
Città #
Ashburn 1.864
Singapore 1.730
Fairfield 1.558
Hong Kong 1.089
San Jose 1.063
Woodbridge 1.036
Houston 780
Milan 716
Chandler 706
Seattle 666
Cambridge 532
Wilmington 523
Dallas 509
Council Bluffs 479
Beijing 475
Ann Arbor 473
Nyköping 470
New York 394
Jacksonville 384
Los Angeles 302
Rome 293
Munich 285
Lauterbourg 282
Helsinki 217
Boardman 179
Lawrence 179
Roxbury 178
Ho Chi Minh City 175
Nanjing 173
Santa Clara 170
Columbus 147
Abidjan 134
São Paulo 134
Hanoi 129
Bari 127
Buffalo 127
Falkenstein 125
Des Moines 108
Jakarta 88
Princeton 88
Chicago 84
London 82
Brooklyn 79
Frankfurt am Main 72
Dong Ket 68
Montreal 68
San Diego 68
Figino 64
Inglewood 64
Warsaw 62
Atlanta 58
Tokyo 55
Turin 55
Orem 50
Mexico City 48
Moscow 47
Phoenix 46
Rio de Janeiro 46
Stockholm 46
Toronto 46
Denver 44
San Francisco 43
Turku 42
Brussels 41
Johannesburg 41
Hebei 40
Naples 40
Nuremberg 38
Shenyang 36
Chennai 34
Curitiba 34
Dublin 34
Nanchang 31
Paris 31
Jiaxing 30
Quito 30
Belo Horizonte 29
Brasília 29
Baghdad 26
Mumbai 26
Tianjin 26
Da Nang 25
Guayaquil 25
Lahore 25
Palermo 25
Salt Lake City 25
Dearborn 24
Amsterdam 23
Haiphong 23
Pune 23
Boston 22
Nairobi 22
Tashkent 22
Guangzhou 21
Poplar 21
The Dalles 21
Amman 20
Ankara 20
Caracas 20
Düsseldorf 20
Totale 21.447
Salva come PNG Salva come JPEG
Nome #
Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study 424
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 388
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 370
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 246
First Case of Paraphimosis as a Severe Complication of Monkeypox 242
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 226
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 214
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 207
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 202
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 200
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 194
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 188
An outbreak of HIV-1 BC recombinants in Southern Italy 187
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 182
Potential diagnostic properties of chest ultrasound in thoracic tuberculosis—A systematic review 181
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 179
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 179
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 176
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study 175
A 75-year-old woman presenting with nasal vestibulitis 175
Lung Ultrasound Is Useful for Evaluating Lung Damage in COVID-19 Patients Treated with Bamlanivimab and Etesevimab: A Single-Center Pilot Study 174
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 173
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 170
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 166
The elderly and direct antiviral agents: Constraint or challenge? 165
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 162
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 161
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 161
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 160
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 160
A 75-year-old woman presenting with nasal vestibulitis 158
First Case of Candida Auris Sepsis in Southern Italy: Antifungal Susceptibility and Genomic Characterisation of a Difficult-to-Treat Emerging Yeast 156
Knowledge, attitudes, and practices about HIV and other sexually transmitted infections among High School students in Southern Italy: A cross-sectional survey 155
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 154
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 154
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 154
Co-receptor switch during HAART is independent of virological success 153
Splenic abscesses as a first manifestation of Crohn's disease: A case report 153
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 153
Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives 150
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 150
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 150
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 149
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. 149
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 149
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 148
Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review 147
Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique 147
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 147
Mortality in migrants living with HIV in western Europe (1997-2013): A collaborative cohort study 146
Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study 144
Chronic Endometritis and Antimicrobial Resistance: Towards a Multidrug-Resistant Endometritis? An Expert Opinion 144
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 144
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 144
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 144
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 144
The at risk child clinic (ARCC): 3 years of health activities in support of the most vulnerable children in Beira, Mozambique 143
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study 142
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 140
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 140
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? 140
Gaining back what is lost: recovering the sense of smell in mild to moderate patients after COVID-19 140
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 140
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 139
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 139
Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study 139
A Challenging Case of Visceral Leishmaniasis 138
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 138
Are the proposed env mutations actually associated with resistance to maraviroc? 137
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 137
Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection 137
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 136
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 136
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 136
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 134
Multidisciplinary Approach in the Treatment of Descending Necrotizing Mediastinitis: Twenty-Year Single-Center Experience 133
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections 132
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 132
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 132
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 131
Pulmonary Artery Filling Defects in Covid-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication? 131
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 130
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 130
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 130
Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients 129
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 129
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 129
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs? 128
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 128
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 127
Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010. 127
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 126
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program 126
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance and Herpesvirus Reactivation: A Double Face of Janus? 126
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. 125
Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review 125
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 124
Tuberculosis and diabetes: Current state and future perspectives 124
Monkeypox Virus Infections in Southern Italy: Is There a Risk for Community Spread? 123
"In vitro" spontaneous production of B-chemokines by endocervical and endometrial short-term bioptic cultures 122
Totale 15.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.159
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.159
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.057 0 0 21 61 52 105 81 90 81 93 180 293
2022/20232.069 315 202 148 142 224 292 38 283 307 18 54 46
2023/20241.140 80 214 68 85 110 275 37 41 28 36 40 126
2024/20254.969 125 90 311 142 99 418 542 513 263 343 654 1.469
2025/202614.531 1.604 790 1.138 1.686 1.522 849 1.366 449 1.569 1.370 628 1.560
2026/20271.852 635 838 379 0 0 0 0 0 0 0 0 0
Totale 34.081